{"filings":[{"id":101337,"accession_number":"0001213900-26-023022","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CPHI subsidiary acquires patent for $6.93M via stock; issues 12.6M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hainan Helpson acquires patent for Prinsepia Utilis Esterol Sublingual Tablets from Xiaoyan Zhang.","Transfer price of $6.93M paid as 12.6M restricted shares of CPHI at $0.55 per share.","Patent granted 2018, expires 2038; transferor provides technical services.","Shares issued under Regulation S exemption as offshore transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101336,"accession_number":"0001213900-26-014338","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"China Pharma Holdings acquires topiroxostat nanoemulsion patent for $8.82M in stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Transfer price of $8.82M paid in 12.6M restricted shares at $0.70/share; closing by Feb 20, 2026.","Transferor Xiaoyun Chen to provide technical services including R&D and registration.","Transferor also entitled to 3% of net profit from product after commercial launch.","Patent covers Topiroxostat Nanoemulsion and method; patent expires July 2036."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101335,"accession_number":"0001213900-26-001785","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"China Pharma Holdings shareholders approve reverse stock split up to 1:20 at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected independent directors Gene Michael Bennett, Yingwen Zhang, Baowen Dong (3,500,418+ votes for each).","Approved reverse stock split up to 1:20 (3,500,256 for, 780 against); Board has discretion on timing.","Approved Amendment No.3 to the Amended and Restated 2010 Long-Term Incentive Plan (3,500,258 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117702,"accession_number":"0001213900-25-125299","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"China Pharma subsidiary acquires Ipragliflozin patent for $9.8M in stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Hainan Helpson enters Technology Transfer Agreement to acquire Ipragliflozin tablet patent from Juan Zhang.","Total consideration: $9.8 million paid in 7,000,000 restricted CPHI shares at $1.40 per share.","Transferor to provide technical services including product R&D, registration materials, and application.","Shares issued under Regulation S to non-U.S. person, unregistered and exempt from Securities Act registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117701,"accession_number":"0001213900-25-120129","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"China Pharma subsidiary to acquire captopril microcapsule patent for $6.3M in stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hainan Helpson subsidiary to receive Captopril microcapsule invention patent and preparation method from Lijie Tang.","Transfer price of $6.3 million paid via 3,500,000 shares of CPHI common stock at $1.80 per share.","Transferor to provide technical services including product R&D, registration materials, and application support.","Shares issued as unregistered securities under Regulation S to a non-U.S. person."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150892,"accession_number":"0001213900-25-029000","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"China Pharma Holdings announces 1-for-10 reverse stock split effective April 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio 1:10, effective April 15, 2025, trading to begin on split-adjusted basis.","Board fixed ratio on March 26, 2025; authorized by board October 22, 2024 and stockholders December 22, 2024.","No fractional shares issued; any fractional shares rounded up to whole number.","Stockholders' percentage interest remains unchanged except for fractional share adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186878,"accession_number":"0001213900-24-112685","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"China Pharma rescinds Dec 12 securities purchase agreement; deal void ab initio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Dec 23, 2024, company and an unnamed investor agreed to rescind the Dec 12 securities purchase agreement.","The rescission renders the agreement void from the beginning, as disclosed in prior 8-K filed Dec 13, 2024.","No details on investor or financial impact provided; agreement termination may affect expected capital infusion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186877,"accession_number":"0001213900-24-112658","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"China Pharma shareholders approve reverse stock split at 1:10–1:20; all directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected: Zhilin Li, Heung Mei Tsui (non-independent), Gene Michael Bennett, Yingwen Zhang, Baowen Dong (independent).","Amendment to allow reverse stock split at ratio between 1:10 and 1:20 approved; board retains discretion to effect.","Amendment No.2 to the 2010 Long-Term Incentive Plan approved by shareholders.","Advisory vote on executive compensation approved; frequency set at every three years.","Annual meeting held Dec 22, 2024; quorum of ~52% (9,688,133 shares) of outstanding stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186876,"accession_number":"0001213900-24-108617","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"China Pharma enters into up to $600,000 at-the-market equity offering with institutional investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SPA signed Dec 12, 2024 for up to $600K of common stock at market price, floor $0.15.","Commitment period Dec 12 – Dec 31, 2024; investor has sole discretion to purchase.","Pricing: lower of prior day close or 5-day avg; repricing if delivery delayed; MFN clause for 30 days.","Investor may return shares within one business day for any reason; no minimum offering amount.","Shares issued under existing S-3 shelf (File 333-276481); proceeds not determinable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219811,"accession_number":"0001213900-24-047965","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"China Pharma extends convertible note maturity to Aug. 2025; minimum monthly payment cut 75%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity date of $557,735 convertible note (Streeterville Capital) extended to August 19, 2025.","Extension fee equal to 2% of outstanding balance added to principal; balance post-fee is $557,735.","Minimum monthly redemption amount reduced from $150,000 to $37,182.33 per month.","Original note principal was $5,250,000 issued November 2021; prior amendment in April 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219810,"accession_number":"0001213900-24-040851","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"China Pharma terminates auditor BF Borgers after SEC denies its practice privilege; appoints Enrome LLP","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SEC issued Rule 102(e) Order against BF Borgers CPA PC on May 3, 2024, barring it from appearing or practicing before the SEC as an accountant.","China Pharma terminated Borgers as independent auditor on May 7, 2024, with audit committee approval.","Audit committee engaged Enrome LLP as new independent registered public accounting firm, effective May 7, 2024.","No disagreements or reportable events occurred with Borgers during the past two fiscal years through termination.","Borgers' audit reports for FY2023 and FY2022 contained a going-concern qualification but no adverse opinion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239584,"accession_number":"0001213900-24-027972","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"China Pharma regains NYSE American compliance after reverse stock split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received NYSE American notice on March 27, 2024 confirming compliance with continued listing standards.","Resolved low selling price deficiency (Section 1003(f)(v)) via 1-for-5 reverse stock split on March 6, 2024.","\".BC\" indicator to be removed; company removed from noncompliant issuers list.","NYSE American cautioned that no cure period exists if stock again trades at abnormally low levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239583,"accession_number":"0001213900-24-016507","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"China Pharma announces 1-for-5 reverse stock split effective March 6, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-5 ratio, effective March 6, 2024; every 5 pre-split shares convert to 1 post-split share.","No fractional shares issued; any fractional shares will be rounded up to the next whole number.","Trading continues on NYSE American under symbol CPHI; new CUSIP is 16941T 302.","Split approved by Board on Oct 16, 2023 and by stockholders on Dec 17, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239582,"accession_number":"0001213900-24-011587","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"China Pharma subsidiary acquires psoriasis patent for $1.5M in stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Helpson, a wholly owned subsidiary of China Pharma, entered a Technology Transfer Agreement with Lihua Li to acquire an invention patent for a psoriasis treatment.","Total consideration is $1.5 million, paid via 15 million restricted shares of common stock at $0.10 per share to the transferor and two designees.","If the product launches and generates profit within 10 years, Helpson will pay 10% of annual net profit in cash to the transferor.","Shares will be issued in an offshore transaction exempt from registration under Regulation S of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257107,"accession_number":"0001213900-23-097680","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"China Pharma acquires COPD drug patent for $1.65M in restricted stock; royalty of 15% net profit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subsidiary Helpson enters Technology Transfer Agreement with Tao Liu for a COPD drug combination patent.","Consideration: 15,000,000 restricted shares at $0.11/share ($1.65M) under Regulation S exemption.","Helpson to pay 15% of net profit from product sales annually for 10 years if product is profitable.","Transferor to provide R&D, registration, and technical services in Haikou.","Shares are unregistered and issued in an offshore transaction to a non-U.S. person."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257106,"accession_number":"0001213900-23-096920","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"China Pharma shareholders OK reverse split up to 1:10; NYSE compliance partially restored","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders re-elected directors Bennett, Zhang, Dong; approved amendment to 2010 long-term incentive plan.","Reverse stock split up to 1:10 approved; board retains discretion on whether and when to effect.","NYSE American confirmed compliance with continued listing standards 1003(a)(ii) and (iii); non-compliance with Section 1003(f)(v) persists.","Company remains under '.BC' indicator; NYSE may initiate delisting if non-compliance recurs within 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257105,"accession_number":"0001013762-23-001101","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2023-10-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"NYSE American warns China Pharma of delisting; avg price below $0.20, cure by March 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Sep 27, 2023, NYSE American notified CPHI of noncompliance: 30-day avg stock price below $0.20.","Company must effect a reverse stock split or demonstrate sustained price improvement by Mar 27, 2024.","Continues to address prior stockholders' equity noncompliance from June 2022.","Listing remains on NYSE American during cure period; business operations unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291702,"accession_number":"0001213900-23-031309","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2023-04-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"China Pharma Holdings extends convertible note maturity to May 2024 with Streeterville Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity extended from November 2021 note to May 19, 2024, with an extension fee of 2% of the outstanding balance.","Outstanding balance as of April 12, 2023 was $3,281,970.19; original note principal was $5,250,000.","Conversion price reduced to 82% multiplied by the lowest VWAP during the prior 10 trading days.","New monthly redemption minimum of $150,000; failure to meet triggers a 1% penalty increase to outstanding balance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312471,"accession_number":"0001213900-23-024081","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"China Pharma regains NYSE American price compliance but remains under equity plan with delisting risk","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resolved low selling price deficiency via 1-for-10 reverse stock split on March 6, 2023.","Still non-compliant with stockholders' equity standards (Sections 1003(a)(ii) and (iii)).","Must achieve full compliance by December 15, 2023 or face delisting proceedings.","\".BC\" indicator remains on ticker CPHI.","If average share price falls below $0.20 over 30 days, immediate review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312470,"accession_number":"0001213900-23-014316","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"China Pharma Holdings announces 1-for-10 reverse stock split effective March 6, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-10 ratio, effective March 6, 2023, trading begins on split-adjusted basis at market open.","Every 10 existing shares convert into 1 share; fractional shares rounded up to whole number.","Approved by Board and stockholders at Annual Meeting on December 27, 2022.","Trading symbol remains 'CPHI' on NYSE American; new CUSIP number 16941T-203.","Reverse stock split does not alter any stockholder's percentage interest except for fractional share adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331009,"accession_number":"0001213900-22-084016","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2022-12-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"China Pharma shareholders approve reverse stock split up to 1:10 and increase authorized shares to 500M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio up to 1:10 approved with 30,927,745 votes for, 325,290 against.","Authorized common shares increased from 95M to 500M; approved with 30,084,494 votes for, 1,171,098 against.","Independent directors Gene Michael Bennett, Yingwen Zhang, Baowen Dong elected to serve until next annual meeting.","Amended and Restated 2010 Long-Term Incentive Plan adopted; 27,482,540 votes for, 824,658 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331008,"accession_number":"0001213900-22-077369","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2022-12-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"China Pharma subsidiary acquires ophthalmic oxygen therapy patent rights for $2.1M in stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hainan Helpson acquires utility model patent (ZL 2022 2 0394857.6) and invention patent application for ophthalmic oxygen enriched atomization device from Chengdu Bonier.","Transfer price: RMB 15M (~$2.1M) paid via 11.1M CPHI shares at $0.1349/share within 10 days under Regulation S exemption.","Bonier provides 10-year technical services including product R&D, registration, and must secure Class II medical device registration within one year.","Service fee: 15% of net profit from product sales annually for 10 years, contingent on invention patent grant; if not granted, no service fee owed.","Stock issuance is unregistered and exempt under Regulation S; shares to a non-U.S. person in an offshore transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331007,"accession_number":"0001213900-22-077304","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2022-12-02T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"China Pharma receives NYSE American deficiency notice for equity shortfall","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $2.8M as of Sept 30, 2022 below the $4.0M minimum required by Section 1003(a)(ii).","Company has reported net losses in four most recent fiscal years ended Dec 31, 2021.","Must regain compliance with equity standard by Dec 15, 2023, and price noncompliance by March 26, 2023.","NYSE American accepted a plan on Aug 29, 2022 to cure equity noncompliance; failure to progress may trigger delisting.","Common stock (CPHI) continues trading with .BC indicator while company attempts to cure deficiencies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348553,"accession_number":"0001213900-22-060675","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"China Pharma (CPHI) gets NYSE American deficiency notice; avg price below $0.20, must cure by March 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Average stock price below $0.20 over 30 days as of Sept 22, 2022 triggers continued listing noncompliance.","NYSE American requires reverse stock split or sustained price improvement by March 26, 2023 to maintain listing.","Company also subject to prior stockholders' equity noncompliance letter from June 2022.","Stock continues trading on NYSE American while company pursues compliance measures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365281,"accession_number":"0001213900-22-034328","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"CPHI receives NYSE American delisting notice for insufficient stockholders' equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity was $5.3M as of March 31, 2022, below the $6.0M minimum required under Section 1003(a)(iii).","Company must submit a compliance plan by July 15, 2022 to regain compliance by December 15, 2023.","CPHI stock will continue trading on NYSE American under symbol CPHI with added '.BC' designation.","Failure to submit or comply with the plan may result in commencement of delisting proceedings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402771,"accession_number":"0001213900-21-067912","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2021-12-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Annual meeting elects five directors, approves incentive plan amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 55% (35,348,061 shares) present at Dec 26, 2021 annual meeting.","All five director nominees elected: Zhilin Li, Heung Mei Tsui, Gene Michael Bennett, Yingwen Zhang, Baowen Dong.","Amendment No.2 to 2010 Long-Term Incentive Plan approved (25,917,951 for, 94,918 against, 7,791 abstentions)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402770,"accession_number":"0001213900-21-061610","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2021-11-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"China Pharma raises $5M via convertible note to Streeterville Capital with 5% interest and 15-month maturity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued unsecured convertible promissory note for $5.25M principal ($5M net proceeds after $250K OID) to Streeterville Capital.","Note carries 5% annual interest; upon default, interest rises to 22% and balance accelerates with 15% or 5% penalty.","Company reserved 30M common shares for conversion; conversion price at 85% of lowest 10-day VWAP during prior 10 trading days.","Proceeds used for general working capital; Streeterville's consent required for fundamental transactions.","Company must file prospectus supplement within 30 days to register up to $5M of common stock for investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":421666,"accession_number":"0001213900-21-048212","cik":1106644,"company_name":"CHINA PHARMA HOLDINGS, INC.","ticker":"CPHI","form_type":"8-K","filed_at":"2021-09-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"China Pharma issues 1.76M shares to CEO to offset accrued compensation; grants option to director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved 1,760,000 shares to CEO Zhilin Li at $0.67/share to partially offset $1,666,706 in accrued unpaid cash compensation.","Unpaid cash compensation reduced from $1,666,706 to $487,506 after share issuance.","Director Gene Michael Bennett granted immediate-vest incentive stock option to purchase 65,000 shares at $1.47/share, expiring Sept 9, 2024.","Options granted under 2010 Long-Term Incentive Plan; shares/options vest immediately with no restrictions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30496859.180526316,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}